PINK:IDRSF
Idorsia Ltd Stock News
$2.88
+0 (+0%)
At Close: Jun 28, 2024
Allschwil, Switzerland – June 21, 2024 Idorsia Ltd (SIX: IDIA) announced today that its novel treatment for chronic insomnia has been awarded the prestigious Prix Galien Suisse 2024 innovation prize
Idorsia holds its Annual General Meeting of Shareholders
05:00am, Thursday, 13'th Jun 2024
Allschwil, Switzerland – June 13, 2024 At today's Annual General Meeting (AGM) of Idorsia Ltd (SIX: IDIA) held in Basel, Switzerland, shareholders voted in favor of all proposals by the Board of Dir
Idorsia issues invitation to the 2024 Annual General Meeting of Shareholders
01:00am, Thursday, 23'rd May 2024
Allschwil, Switzerland – May 23, 2024 Idorsia Ltd (SIX: IDIA) today issued the invitation to the upcoming Annual General Meeting (AGM) of Shareholders on behalf of the Board of Directors. The meetin
Idorsia Ltd (IDRSF) Q1 2024 Earnings Call Transcript
06:20pm, Tuesday, 21'st May 2024
Idorsia Ltd (OTC:IDRSF) Q1 2024 Results Conference Call May 21, 2024 8:00 AM ET Company Participants Andrew Weiss - SVP, Head of Investor Relations & Corporate Communications Jean-Paul Clozel - Chief
Idorsia announces changes to Idorsia Executive Committee and Board of Directors
01:00am, Tuesday, 21'st May 2024
Ad hoc announcement pursuant to Art. 53 LR Jean-Paul Clozel to retire as CEO and stand for election as Chairman of the Board of Directors Mathieu Simon to stand for re-election to the Board – taking
Idorsia announces financial results for the first quarter 2024 – advancing the company with renewed vigor
12:50am, Tuesday, 21'st May 2024
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – May 21, 2024 Idorsia Ltd (SIX: IDIA) today announced its financial results for the first quarter of 2024.
Idorsia announces financial results for the full year of 2023 – Adapting the company to create sustainable value
12:40am, Tuesday, 21'st May 2024
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – May 21, 2024 Idorsia Ltd (SIX: IDIA) today announced its financial results for the full year of 2023.
Invitation to Idorsia's Full Year 2023 and Q1 2024 Financial Reporting webcast and conference call
11:45am, Tuesday, 14'th May 2024
Idorsia will publish its Full Year 2023 and Q1 2024 Financial Reporting on Tuesday May 21, 2024, at 07:00 CEST. An investor conference call and webcast will be held to discuss the results on the same
Idorsia increases the consent fee in connection with the proposed restructuring of the 2024 convertible bond
12:00pm, Wednesday, 01'st May 2024
Ad hoc announcement pursuant to Art. 53 LR The proposed consent fee will be increased to 8'000'000 Idorsia shares.
Idorsia publishes an invitation to a bondholder meeting
01:00am, Tuesday, 23'rd Apr 2024
Ad hoc announcement pursuant to Art. 53 LR A bondholder meeting will take place on May 6, 2024, to vote on proposals to amend the terms of the outstanding convertible bonds maturing on July 17, 2024,
Idorsia publishes a Financial Status required for an upcoming bondholder meeting
01:00am, Wednesday, 17'th Apr 2024
Ad hoc announcement pursuant to Art. 53 LR Unaudited Financial Status as of March 31, 2024, required for an upcoming bondholder meeting, now available on the company website Bondholder meeting now pla
Idorsia takes steps to address short-term liquidity needs
01:00am, Thursday, 11'th Apr 2024
Ad hoc announcement pursuant to Art. 53 LR A bondholders meeting is expected to take place on April 30, 2024, to request the right to repay the bonds maturing in 2024, fully or partially in shares of
Idorsia thanks Guy Braunstein for his years of service as he retires
02:00am, Friday, 22'nd Mar 2024
Allschwil, Switzerland – March 22, 2024 Idorsia Ltd (SIX: IDIA) today announced that Guy Braunstein, who has served as Chief Medical Officer (CMO) since 2022 and Head of Global Clinical Development
Ad hoc announcement pursuant to Art. 53 LR TRYVIO™ (aprocitentan) is indicated for the treatment of hypertension in combination with other antihypertensive drugs, to lower blood pressure in adult pa
Ad hoc announcement pursuant to Art. 53 LR TRYVIO™ (aprocitentan) is indicated for the treatment of hypertension in combination with other antihypertensive drugs, to lower blood pressure in adult pa